Patents Examined by David J. Blanchard
-
Patent number: 11369812Abstract: A non-irritation, non-blurring ophthalmic sunscreen composition contains a liquid vehicle base, such as an artificial tear formulation or an ophthalmic suspension or ointment. The composition includes at least one inorganic and/or at least one organic active ingredient. The inorganic active ingredients may include, but not be limited to zinc oxide, titanium dioxide, iron oxide, zirconium oxide, and cerium oxide. The organic active ingredients may include, but not be limited to dioxybenzone, octinoxate, octisalate, homosalate, avobenzone, octocrylene, para-aminobenzoic acid, cinoxate, methyl anthranilate, octocrylene, padimate O, ensulizole, sulisobenzone, trolamine salicylate, and ecamsule.Type: GrantFiled: April 10, 2020Date of Patent: June 28, 2022Assignee: A. Ebbie Soroudi, M.D., M.S., A Professional Medical CorporationInventor: A. Ebbie Soroudi
-
Patent number: 11344538Abstract: The invention provides methods for the treatment of myopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant, a viscosity agent, a polyol and/or a selective ?-2 adrenergic receptor agonist.Type: GrantFiled: February 20, 2020Date of Patent: May 31, 2022Assignee: LENZ THERAPEUTICS, INC.Inventor: Gerald Horn
-
Patent number: 11345599Abstract: Particulate material comprising rough mesoporous hollow nanoparticles. The rough mesoporous hollow nanoparticles may comprise a mesoporous shell, the external surface of which has projections thereon, the projections having smaller sizes than the particle size. The particulate material may be used to deliver active agents, such as insecticides and pesticides. The active agents can enter into the hollow core of the particles and be protected from degradation by sunlight. The rough surface of the particles retains the particles on plant leaves or animal hair. Methods for forming the particles are also described. Carbon particles and methods for forming carbon particles are also described.Type: GrantFiled: April 18, 2016Date of Patent: May 31, 2022Assignee: THE UNIVERSITY OF QUEENSLANDInventors: Chengzhong Yu, Meihua Yu, Hongwei Zhang, Yusilawati Ahmad Nor, Hao Song
-
Patent number: 11337936Abstract: Described are transdermal drug delivery compositions comprising amphetamine, methods of making them and therapeutic methods using them. The compositions are provided in a flexible, finite form (e.g. “patch”-type systems) and comprise a polymer matrix that includes amphetamine and an acrylic block copolymer.Type: GrantFiled: March 12, 2014Date of Patent: May 24, 2022Assignee: NOVEN PHARMACEUTICALS, INC.Inventors: Robert Lambert, Weijun Lu, Jun Liao
-
Patent number: 11331321Abstract: The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB.Type: GrantFiled: December 6, 2013Date of Patent: May 17, 2022Assignee: CEVA SANTE ANIMALEInventors: Anne-Claire Le Meur, Florence Guimberteau
-
Patent number: 11298318Abstract: Ultra-small Lipid Structures (USLS) with an average mean particle diameter of less than 100 nm are made using a single step process by diluting a hydro-organic solution containing lipids and passenger compounds. These particles are capable of sequestering the passenger molecules and self-assemble in a single process step into USLS. The USLS have applications in, for example, agricultural, cosmetics, pharmaceutical and food and beverage industries.Type: GrantFiled: April 13, 2016Date of Patent: April 12, 2022Assignee: FOUNTAIN TECHNOLOGIES INTERNATIONAL, LLCInventor: Michael Fountain
-
Microneedle particles, compositions, and methods of treatment and delivering a substance of interest
Patent number: 11291816Abstract: Provided herein are microneedle particles, compositions that include microneedle particles, methods of treating skin, and methods of delivering a substance of interest. The microneedle particles may include one or more microneedles, and the microneedle particles may be configured to prevent the entire microneedle particle from penetrating the biological tissue. The microneedle particles may be dispersed in a liquid medium to form a composition. A biological tissue may be contacted with the microneedle particles to pre-treat the biological tissue, and a substance of interest may be applied to the pre-treated biological tissue.Type: GrantFiled: March 1, 2017Date of Patent: April 5, 2022Assignee: Georgia Tech Research CorporationInventors: Andrew Tadros, Mark R. Prausnitz -
Patent number: 11285087Abstract: Disclosed are a cosmetic composition having increased skin contact and makeup persistence and a method of manufacturing the same. The method includes: forming a powder continuous phase by rapidly mixing a powder and a film-forming agent; and obtaining a cosmetic composition in which a surface of the powder is compounded with the film-forming agent by heating the powder continuous phase for a predetermined time. In an embodiment, the cosmetic composition is manufactured by the method. In an embodiment, the cosmetic composition includes 5 wt % to 30 wt % of a powder, 0.1 wt % to 10 wt % of a film-forming agent, 10 wt % to 30 wt % of a silicone oil, and 0.1 wt % to 10 wt % of a spherical powder.Type: GrantFiled: February 6, 2020Date of Patent: March 29, 2022Assignee: COSMECCA KOREA CO., LTD.Inventors: Hyun Dae Cho, Byoung Moon Kim, Yeen Ji Kim, Goo Ho Kwon, Jin Young Kim
-
Patent number: 11260024Abstract: Biopharmaceuticals, such as vaccine agents and probiotics, are encapsulated in carbohydrate-glass particles and embedded in an amorphous polymer substrate to produce polymeric compositions containing ambient-temperature stable biopharmaceuticals for syringeless administration to patients such as via dissolvable films, micro-needle patches and similar medical delivery devices. The amorphous polymer substrate is soluble in both water and a volatile organic solvent, yet the carbohydrate-glass particles are insoluble in the volatile organic solvent.Type: GrantFiled: March 28, 2019Date of Patent: March 1, 2022Assignee: UNIVERSAL STABILIZATION TECHNOLOGIES, INCInventor: Victor Bronshtein
-
Patent number: 11246831Abstract: Aqueous dispersions of chemically and physically stable particles for use in delivery of active pharmaceutical ingredients and processes for their production and use to enhance a biological response to an active pharmaceutical ingredient and prophylactically or therapeutically treat a subject are provided. Vaccines, wherein the active pharmaceutical ingredient is a solution of subunit vaccine antigen mixed with a colloidal dispersion of electrically charged particles and use of such vaccines in immunization are also provided.Type: GrantFiled: March 31, 2008Date of Patent: February 15, 2022Assignee: PARTICLE SCIENCES, INC.Inventors: Andrew Loxley, Mark Mitchnick, David Fairhurst, Christy Ann Eatmon
-
Patent number: 11246816Abstract: Described herein is a shampoo composition and methods of using the same, the shampoo composition including a Class I and/or Class II chelant, a detersive surfactant, and a carrier.Type: GrantFiled: June 22, 2017Date of Patent: February 15, 2022Assignee: The Procter and Gamble CompanyInventors: Jennifer Mary Marsh, Casey Patrick Kelly, Mark Robert Sivik
-
Patent number: 11234935Abstract: The invention provides a method of inducing satiety in a subject comprising a step of orally administering a composition comprising an effective amount of a first agent capable of inducing satiety and of a second agent capable of augmenting the satiety-inducing effect of the first agent. Also disclosed are compositions for carrying out the method and a body weight management system comprising such compositions in combination with a device configured for the collection, storage and/or display of information relating to a subject's response to a predefined therapeutic regimen of orally administering the composition.Type: GrantFiled: July 7, 2016Date of Patent: February 1, 2022Assignee: PERORA GMBHInventor: Dirk Vetter
-
Patent number: 11234927Abstract: The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating.Type: GrantFiled: June 29, 2021Date of Patent: February 1, 2022Inventor: Praful Doshi
-
Patent number: 11235086Abstract: A method of coating a peptide or protein useful for improving the cellular activity related to bone growth on an inorganic particle comprises the steps of freezing the residual liquid present on uncoated and or coated inorganic particles, and drying the uncoated or coated inorganic particles after freezing the residual liquid, the drying comprising causing the frozen residual liquid to sublime under vacuum. Further disclosed embodiments of the invention include further processes for forming inorganic particles coated with a peptide or protein useful for improving cellular activity related to bone growth and medical devices comprising the coated particles.Type: GrantFiled: February 21, 2019Date of Patent: February 1, 2022Assignee: Cerapedics, Inc.Inventors: Jevon Nyemscek, Jessica Stufflet, Nicolas Roscioli, Doug Millard, Katherine Suzanne Davis, Nolan Chase Hannigan, Tristan Stuart Barnes, Jerome Connor
-
Patent number: 11219631Abstract: A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions.Type: GrantFiled: August 22, 2018Date of Patent: January 11, 2022Assignee: Vyne Pharmaceuticals Inc.Inventors: Dov Tamarkin, Enbal Ziv, Yohan Hazot, David Schuz
-
Patent number: 11219665Abstract: The present invention provides a method for preparing a bone protein preparation which contains for example growth factors. The present invention also provides a bone protein preparation obtained by the method and paste, putty, pellet, disc, block, granule, osteogenic device or pharmaceutical composition containing said bone protein preparation.Type: GrantFiled: May 5, 2020Date of Patent: January 11, 2022Assignee: BBS-Bioactive Bone Substitutes OYJInventors: Hanna Tölli, Juha-Matti Närhi, Harri Lumme, Elli Birr, Oili Hietala, Mikko Viitanen, Merja Haikola, Pekka Jalovaara, Bo Kenneth Sandström
-
Patent number: 11213473Abstract: A composition to improve hyperpigmentation is disclosed. The composition has one or more active ingredients such as tranexamic acid, niacinamide, arbutin, and Vitamin C. The composition has water, caprylic/capric triglyceride, C12-15 Alkyl Benzoate, Isononyl Isononanoate, Silica, Glyceryl Stearate and PEG-100 Stearate, Cetearyl Alcohol and Ceteareth-20, Xylitylglucoside and Anhydroxylitol and Xylitol, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Polysorbate 60, Phenoxyethanol and Ethylhexylglycerin, Citric Acid, Titanium Dioxide, Citrus oil, sh-Polypeptide-22, and sh-Oligopeptide-1. The composition is a non-HQ formulation that provides equal or greater efficacy with a reduced adverse reaction profile to improve skin hyperpigmentation, such as melasma, post-inflammatory hyperpigmentation, and solar lentigines. The composition reduces skin damage and provides toning to the skin.Type: GrantFiled: September 18, 2020Date of Patent: January 4, 2022Inventor: Christopher Zoumalan
-
Patent number: 11207266Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.Type: GrantFiled: September 6, 2019Date of Patent: December 28, 2021Assignee: Neurotech, USA, Inc.Inventors: Jeffrey Louis Goldberg, Cahil McGovern, Weng Tao, Konrad A. Kauper
-
Patent number: 11202800Abstract: The present invention relates to the treatment of refractory Emotional Cognitive Disconnect (ECD) through a combination of pharmaceutical agents and therapy. Individual patients are treated with a combination of magnesium, inositol, and N-acetylcysteine along with Vitamin E, Vitamin C, zinc, biotin, alphalipoic acid and lysine as required. The compositions may be administered sequentially or simultaneously in any order and may be formulated in singular or combinatorial dosage forms.Type: GrantFiled: July 5, 2019Date of Patent: December 21, 2021Inventor: Jeanne Fleming
-
Patent number: 11179243Abstract: Implantable devices for orthopedic, including spine and other uses are formed of porous reinforced polymer scaffolds. Scaffolds include a thermoplastic polymer forming a porous matrix that has continuously interconnected pores. The porosity and the size of the pores within the scaffold are selectively formed during synthesis of the composite material, and the composite material includes a plurality of reinforcement particles integrally formed within and embedded in the matrix and exposed on the pore surfaces. The reinforcement particles provide one or more of reinforcement, bioactivity, or bioresorption.Type: GrantFiled: September 18, 2018Date of Patent: November 23, 2021Assignee: HAPPE SPINE LLCInventors: Ryan K. Roeder, Gabriel L. Converse, Stephen M. Smith